Switzerland-based MindMaze is an FDA-approved digital neurotherapeutics company that offers treatments for patients suffering from neurological injuries (including stroke, trauma, dementia, and Parkinson’s disease). It provides a platform (named MindMotion) that assists the patients’ rehabilitation process through game-based digital therapies (such as a movement-tracking game), helping patients regain upper limb functionality after suffering a stroke or other neurophysiological impairment.
In May 2017, the company entered the US market with FDA approval for its hospital-based platform, MindMotion Pro. The platform’s at-home model received FDA clearance in 2018.
In November 2018, the company acquired fellow neuro-rehabilitation tech company Neuro Motor Innovations Corporation (NMI) for an undisclosed amount. Owing to the acquisition, MindMaze acquired a perpetual license for NMI’s rehabilitation technology. NMI’s technology consists of an AI-driven video game designed to treat neurological patients by challenging their cognitive skills. The product usage is not limited to neurotherapeutics but is also beneficial to the healthy aging population. This acquisition will strengthen and enhance MindMaze’s product offerings to patients as a multi-stage platform for neurological therapy.
In May 2021, the company entered a multitude of partnerships. The partnering companies included Peruvian medical biotech company Surgicorp, Saudi Arabian medical company Alkholi, Spanish neurorehabilitation clinic Guttmann Barcelona, and the Switzerland-based rehabilitation center Swiss Rehabilitation. Through the series of new partnerships, the company aims to expand its global presence to the Middle East, Latin America, and Spain and further expand its presence in Switzerland.
In October 2021, the company raised USD 125 million in a funding round led by AlbaCore Capital Group, marking MindMaze's first funding round since February 2016. The company intends to use the fresh funds to commercialize and develop its markets in gamified rehabilitation product offerings, mainly in North America and Europe, and to expand its neuro-restorative portfolio through product development and clinical trials for neurodegenerative diseases.
No investor data is available
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.